One day after AstraZeneca PLC reported third quarter sales and earnings results and announced a licensing deal to bring in an oral glucagon-like peptide 1 (GLP-1) agonist for obesity, CEO Pascal Soriot outlined his thinking on the future of obesity drug development and how AstraZeneca might fit into what is expected to be a crowded market.
Key Takeaways
- CEO Pascal Soriot discussed the company’s goals in obesity drug development and gene therapy R&D during a media briefing in New York.
- The exec downplayed geopolitical tensions in China, where it has a large operation
During a media briefing in New York City on 10 November, Soriot commented on the new obesity deal as well as other topics, like the company’s commitment to gene therapy, tension in China and a new Medicare drug price negotiation program
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
